Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 312.50
Ask: 316.00
Change: -1.50 (-0.48%)
Spread: 3.50 (1.12%)
Open: 310.00
High: 310.00
Low: 310.00
Prev. Close: 311.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director dealings: TUI, Oxford Biomedica board members linked to buys

Wed, 27th Sep 2023 11:24

(Sharecast News) - TUI was among those on the list of director buys on Wednesday after its chief executive officer purchased almost 50,000 shares.

The travel giant said Sebastian Ebel picked up 49,900 shares on 26 September in a single transaction outside a trading venue.

Ebel paid €4.99 for each share, valuing the transaction at a total of €224,325.21 (£194,816.35).

Elsewhere, Oxford Biomedica disclosed a purchase linked to one of its non-executive directors.

The company said Sandra Juliet Ferera Hayden bought 12,000 shares on 26 September in a single transaction on the London Stock Exchange.

Hayden paid 293.5p for each share, valuing the purchase at £35,220.00.

In its disclosure, Oxford Biomedica said Sandra Hayden is a person closely associated with non-executive director Michael Hayden.

At 1304 BST, shares in TUI were up 3.39% in London at 451.6p, while those in Oxford Biomedica were 1.72% weaker at 286.5p.

Reporting by Josh White for Sharecast.com.

More News
12 Mar 2019 10:10

Oxford Biomedica enters research collaboration with Microsoft

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has entered into a research and development collaboration with Microsoft Research, it announced on Tuesday, to improve the yield and quality of next-generation gene therapy vectors using the cloud and machine learning.

Read more
23 Nov 2018 10:59

Oxford BioMedica forms new digital framework initiative

(Sharecast News) - Gene and cell therapy group Oxford BioMedica announced the formation of a new digital framework initiative on Friday, which it said would streamline the production of next-generation medicines.

Read more
25 Oct 2018 10:14

First patient successfully dosed with Oxford BioMedica's OXB-102

(Sharecast News) - Gene and cell therapy group Oxford BioMedica noted on Thursday that its partner, Axovant Sciences - a company developing innovative gene therapies for neurologic and neuromuscular diseases - has announced the successful dosing of the first patient in a clinical study of AXO-Lenti-PD, also known as OXB-102.

Read more
13 Sep 2018 15:46

'Transformative year' sees Oxford Biomedica profit from two huge contracts

(Sharecast News) - Biopharmaceutical company Oxford Biomedica saw its shares rise on Thursday after its first half gross income more than doubled due to two huge contracts.

Read more
22 May 2018 16:13

UK Shareholder Meetings Calendar - Next 7 Days

Wednesday 23 MayBovis Homes GroupSt James's Place Keller GroupGamma Emerging

Read more
4 May 2018 11:57

Oxford BioMedica To Cut Share Capital Through Consolidation (ALLISS)

LONDON (Alliance News) - Oxford BioMedica PLC said Friday it is proposing reducing the issued share capital of the company by a factor of 50 through a share capital consolidation.On Oxford

Read more
15 Mar 2018 11:45

Oxford Biomedica Loss Narrows, Revenue Grows In Transformational 2017

LONDON (Alliance News) - Gene therapy firm Oxford Biomedica PLC said Thursday its 2017 loss narrowed after revenue grew significantly on product progress and finance costs in

Read more
9 Mar 2018 17:16

Oxford BioMedica To Raise GBP21 Million Via Discounted Share Issue (ALLISS)

LONDON (Alliance News) - Oxford BioMedica PLC said Friday it intends to raise GBP20.5 million via a accelerated share book build process to fund the expansion a

Read more
10 Oct 2016 14:19

Oxford BioMedica's RetinoStat achieves 'favourable safety profile' in tests

(ShareCast News) - AIM-listed pharmaceutical Oxford BioMedica's RetinoStat, the first ocular lentiviral gene therapy to be administered in humans, demonstrated a "favourable safety profile with no serious adverse events" in its phase one study. Results of the study, which were previously published i

Read more
28 Jul 2016 09:05

Oxford BioMedica Gets Approval To Manufacture Drugs At New Facilities

Read more
7 Jun 2016 06:48

Oxford BioMedica Signs New Non-Exclusive Licence Deal With MolMed

Read more
2 Jun 2016 11:03

LONDON MARKET MIDDAY: Platinum Firm Gleams Ahead Of ECB, OPEC Outcomes

Read more
2 Jun 2016 09:16

Oxford Biomedica Signs Collaboration Deal With Green Cross LabCell

Read more
31 May 2016 15:04

UK Shareholder Meetings Calendar - Next 7 Days

Read more
24 May 2016 10:42

DIRECTOR DEALINGS: Oxford BioMedica Chairman Ups Interest

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.